1,785 Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART) Bought by Valley National Advisers Inc.

Valley National Advisers Inc. purchased a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,785 shares of the life sciences company’s stock, valued at approximately $63,000.

Several other institutional investors also recently bought and sold shares of the company. Madison Avenue Partners LP grew its position in shares of Integra LifeSciences by 8.0% in the fourth quarter. Madison Avenue Partners LP now owns 1,042,156 shares of the life sciences company’s stock valued at $45,386,000 after purchasing an additional 77,489 shares in the last quarter. Capital Research Global Investors grew its position in shares of Integra LifeSciences by 40.1% in the fourth quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company’s stock valued at $187,149,000 after purchasing an additional 1,228,996 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Integra LifeSciences by 4.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock valued at $70,340,000 after purchasing an additional 63,323 shares in the last quarter. Cooke & Bieler LP grew its position in shares of Integra LifeSciences by 4.4% in the fourth quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock valued at $123,447,000 after purchasing an additional 120,410 shares in the last quarter. Finally, Cardinal Capital Management grew its position in shares of Integra LifeSciences by 1.6% in the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock valued at $962,000 after purchasing an additional 347 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on IART shares. Morgan Stanley lowered their price objective on Integra LifeSciences from $37.00 to $24.00 and set an “underweight” rating for the company in a research report on Tuesday, May 7th. Bank of America lowered their price objective on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a research report on Tuesday, May 7th. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. JMP Securities lowered their price objective on Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 7th. Finally, Oppenheimer cut Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 7th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $33.88.

Insiders Place Their Bets

In related news, Chairman Stuart Essig acquired 52,641 shares of Integra LifeSciences stock in a transaction dated Thursday, May 23rd. The shares were acquired at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the completion of the transaction, the chairman now directly owns 487,922 shares of the company’s stock, valued at $13,900,897.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 3.10% of the stock is owned by company insiders.

Integra LifeSciences Price Performance

NASDAQ:IART traded down $0.46 during trading hours on Wednesday, hitting $28.73. The company’s stock had a trading volume of 833,632 shares, compared to its average volume of 1,107,109. Integra LifeSciences Holdings Co. has a 52-week low of $22.36 and a 52-week high of $46.75. The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.35 and a current ratio of 4.68. The company has a market capitalization of $2.26 billion, a PE ratio of 57.46, a PEG ratio of 1.05 and a beta of 1.11. The business’s 50-day moving average is $28.59 and its two-hundred day moving average is $35.37.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, hitting analysts’ consensus estimates of $0.55. The company had revenue of $368.90 million for the quarter, compared to the consensus estimate of $361.96 million. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. Integra LifeSciences’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.74 earnings per share. As a group, research analysts anticipate that Integra LifeSciences Holdings Co. will post 3.03 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.